161 related articles for article (PubMed ID: 25405915)
1. Erythropoietin levels in patients with sickle cell disease do not correlate with known inducers of erythropoietin.
Pulte ED; McKenzie SE; Caro J; Ballas SK
Hemoglobin; 2014; 38(6):385-9. PubMed ID: 25405915
[TBL] [Abstract][Full Text] [Related]
2. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
3. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
Sharef SW; Al-Hajri M; Beshlawi I; Al-Shahrabally A; Elshinawy M; Zachariah M; Mevada ST; Bashir W; Rawas A; Taqi A; Al-Lamki Z; Wali Y
Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171
[TBL] [Abstract][Full Text] [Related]
4. Sickle cell pain crisis.
Davies SC; Bevan DH
Lancet; 1996 Jan; 347(8996):263. PubMed ID: 8551907
[No Abstract] [Full Text] [Related]
5. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients.
Al-Nood HA; Al-Khawlani MM; Al-Akwa A
Hemoglobin; 2011; 35(1):13-21. PubMed ID: 21250877
[TBL] [Abstract][Full Text] [Related]
6. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea in the treatment of sickle-cell anemia.
Howard LW; Kennedy LD
Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
[TBL] [Abstract][Full Text] [Related]
8. Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease.
Gordeuk VR; Campbell A; Rana S; Nouraie M; Niu X; Minniti CP; Sable C; Darbari D; Dham N; Onyekwere O; Ammosova T; Nekhai S; Kato GJ; Gladwin MT; Castro OL
Blood; 2009 Nov; 114(21):4639-44. PubMed ID: 19724057
[TBL] [Abstract][Full Text] [Related]
9. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
[TBL] [Abstract][Full Text] [Related]
10. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.
Patel DK; Mashon RS; Patel S; Das BS; Purohit P; Bishwal SC
Hemoglobin; 2012; 36(5):409-20. PubMed ID: 22881992
[TBL] [Abstract][Full Text] [Related]
11. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
[TBL] [Abstract][Full Text] [Related]
12. Treatment of sickle cell anemia with hydroxyurea and erythropoietin.
Goldberg MA; Brugnara C; Dover GJ; Schapira L; Charache S; Bunn HF
N Engl J Med; 1990 Aug; 323(6):366-72. PubMed ID: 1695325
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.
Chaine B; Neonato MG; Girot R; Aractingi S
Arch Dermatol; 2001 Apr; 137(4):467-70. PubMed ID: 11295927
[TBL] [Abstract][Full Text] [Related]
14. When should hydroxyurea be used for children with sickle cell disease?
Mueller BU
Pediatrics; 2008 Dec; 122(6):1365-6. PubMed ID: 19047256
[No Abstract] [Full Text] [Related]
15. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
[TBL] [Abstract][Full Text] [Related]
16. Anemia in kidney transplants without erythropoietic agents: levels of erythropoietin and iron parameters.
Florit EA; Hadad F; Rodriguez Cubillo B; De la Flor JC; Valga F; Perez Flores I; Calvo Romero N; Valero San Cecilio R; Barrientos Guzman A; Sanchez Fructuoso A
Transplant Proc; 2012 Nov; 44(9):2590-2. PubMed ID: 23146464
[TBL] [Abstract][Full Text] [Related]
17. A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease.
Zhang X; Shah BN; Zhang W; Saraf SL; Miasnikova G; Sergueeva A; Ammosova T; Niu X; Nouraie M; Nekhai S; Castro O; Gladwin MT; Prchal JT; Garcia JG; Machado RF; Gordeuk VR
Hum Mol Genet; 2016 Oct; 25(20):4601-4609. PubMed ID: 28173069
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea-induced denaturation of normal and sickle cell hemoglobins in vitro.
Roa D; Kopsombut P; Aguinaga MP; Turner EA
J Clin Lab Anal; 1997; 11(4):208-13. PubMed ID: 9219062
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea therapy in sickle cell anemia patients in Curaçao, The Netherlands Antilles.
Saleh AW; Velvis HJ; Gu LH; Hillen HF; Huisman TH
Acta Haematol; 1997; 98(3):125-9. PubMed ID: 9352741
[TBL] [Abstract][Full Text] [Related]
20. Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea.
Olnes M; Chi A; Haney C; May R; Minniti C; Taylor J; Kato GJ
Am J Hematol; 2009 Aug; 84(8):530-32. PubMed ID: 19536844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
